Klaus Peters

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

Elmar A. Joura, Àngels Ulied, Corinne Vandermeulen, Milagrosa Rua Figueroa et autres

at, es, us, be, co, fi, it, de, ee, Ouganda (code pays fourni par la source)

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Nicolas Folschweiller, Ulrich Behre, Marc Dionne, Paolo Durando et autres

be, ca, it, de, us, th, in (code pays fourni par la source)

Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials

Mahboobeh Safaeian, Xavier Castellsagué, Allan Hildesheim, Sholom Wacholder et autres

us, es, be (code pays fourni par la source)

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

Joseph E. Tota, Frank Struyf, Marko Merikukka, Paula González et autres

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

Li‐Min Huang, Thanyawee Puthanakit, Chiu Cheng-Hsun, Ren-Bin Tang et autres

tw, th, de, it, ca, in (code pays fourni par la source)

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

Joseph E. Tota, Frank Struyf, Marko Merikukka, Paula González et autres

us (code pays fourni par la source)

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

Suzanne M. Garland, Jorma Paavonen, Unnop Jaisamrarn, Paulo Naud et autres

au, fi, th, br, mx, tw, es, us, ph, de, be (code pays fourni par la source)

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

Barbara Romanowski, Tino F. Schwarz, Linda Ferguson, Klaus Peters et autres

ca, de, us, in, nl, be (code pays fourni par la source)

Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

Frank Struyf, Brigitte Colau, Cosette M. Wheeler, Paulo Naud et autres

be, us, br, au, nl, tw, mx, fi, ph, de, es, gb (code pays fourni par la source)

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial

Xavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, Cosette M. Wheeler et autres

es, fi, th, us, au, br, tw, mx, de, ph, gb, be, ca, nl, ch (code pays fourni par la source)

Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

Xavier Castellsagué, Paulo Naud, Song-Nan Chow, Cosette M. Wheeler et autres

es, br, tw, us, ph, fi, th, au, ca, mx, gb, de, be (code pays fourni par la source)

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson, Murdo Ferguson et autres

ca, de, us, in, nl, be (code pays fourni par la source)